Sahajanand Medical IPO IPO
· UpcomingMainboard IPO · Registrar: MUFG Intime India Private Limited
GMP last updated: 13 Oct 2026, 5:57 pm
Current GMP
₹35
Estimated listing gain: ~10.2%
About Sahajanand Medical IPO
Sahajanand Medical Technologies Limited is a prominent R&D-driven medical device developer specializing in vascular intervention and structural heart solutions, such as coronary stents and TAVI devices. Founded in 2001 and backed by institutional investors like Samara Capital, the company enjoys strong market standing in India and expanding international footprints across more than 76 countries. Its competitive edge lies in rigorous clinical validations, proprietary technological advancements, and cost-effective manufacturing capabilities.
| Price Band | ₹327 – ₹344 |
| Lot Size | 43 |
| Minimum Investment | ₹14,792 |
| Issue Details | Expected Issue Size: ~₹475 Cr | Entirely Offer for Sale (OFS) of up to 1,38,22,116 Equity Shares |
| Open Date | 2026-10-15 |
| Close Date | 2026-10-19 |
| Allotment Date | 2026-10-20 |
| Listing Date | 2026-10-22 |
| Listing Exchanges | BSE, NSE |
| Registrar | MUFG Intime India Private Limited |
| Lead Manager | Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities and Capital Markets, Nuvama Wealth Management |
| Quota Details | QIB: 50% | NII: 15% | Retail: 35% |
Financials
FY25: Total Revenue ₹538.60 Cr, Net Loss ₹7.92 Cr | FY24: Total Revenue ₹478.32 Cr, Net Loss ₹34.46 Cr | Total Assets (FY25): ₹1,008.11 Cr
Subscription Status
Expected moderate to high demand led by institutional and high-net-worth investors tracking niche healthcare plays.
Fundamentals & Outlook
Short Term
bullish
Mid Term
bullish
Long Term
bullish
Our Analysis
Sahajanand Medical holds a strong leadership position in domestic and emerging vascular device segments backed by robust global clinical data. Key risks include heavy regulatory compliance requirements, intense competition from global medtech giants, and historical net losses. However, long-term industry tailwinds in structural heart care offer a positive outlook for investors with higher risk appetites.
How we track GMP: Grey Market Premium is manually tracked and updated by the Stocksbaaz team from grey market activity. It is an unofficial indicator, not verified or endorsed by SEBI, NSE, or BSE, and should not be the sole basis for any investment decision.
Read our full Disclaimer before applying for this IPO.